Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Janssen loses patent fight over arthritis drug

by Glenn Hess, special to C&EN
August 29, 2016 | A version of this story appeared in Volume 94, Issue 34

A key patent for Remicade (infliximab), a top-selling rheumatoid arthritis drug made by Johnson & Johnson subsidiary Janssen Biotech, is invalid, a federal court has ruled. The decision, which Janssen pledged to appeal, is a victory for Pfizer-owned Hospira Healthcare and Celltrion Healthcare. The companies plan to launch a biosimilar version of Remicade in the U.S. later this year. A federal trial court in Massachusetts found that the antibodies covered by the disputed patent, which expires in 2018, were already disclosed in an earlier patent. In a separate proceeding regarding this patent, the U.S. Patent & Trademark Office came to a similar conclusion, a decision that Janssen is appealing. Meanwhile, the federal court is also considering the validity of a second Janssen patent related to Remicade which expires in 2027. Pfizer’s Hospira has exclusive U.S. marketing rights to an infliximab biosimilar that would be made by Celltrion, a South Korean drugmaker. Remicade is J&J’s best-selling drug. In 2015, this biologic drug generated U.S. sales of nearly $4.5 billion and worldwide sales of almost $6.6 billion.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.